Doctor of Medical Sciences Assesses the Potential of Phytopharmaceuticals in the Treatment of Spinal Cord Injuries

 

Located in the Meeting Room dr. A A. Made Djelantik Unud FK Building, Denpasar, a Doctoral Promotion exam was held with the promovedus candidate, dr. Dewa Putu Wisnu Wardhana, Sp.BS(K)., FICS., with the dissertation title "Moleac 901 Administration Reduces Neuron-Glial Antigen 2 Expression, Caspase-3 Expression, Increases Interleukin-10 Levels, Improves Histopathological Features of the Spinal Cord, and Functions Motor in Wistar Rats Induced by Severe Degree of Spinal Cord Injury in the Chronic Phase." (28/8/2023)

 

Spinal cord injury (CMS) is a sudden neurological disorder, resulting in death or disability in motor, sensory and autonomic functions. Post CMS therapeutic strategies are designed to act as neuroprotection, neurogenesis, and against neurodegenerative processes. Moleac (MLC) 901 is a phytopharmaca containing important molecules capable of creating microconditions to facilitate the amplification and differentiation of nerve cell progenitors. This study aims to determine the effect of MLC901 administration on Neuron-Glial Antigen (NG) 2 expression, Caspase-3 expression, Interleukin (IL)-10 levels, histopathological features of the spinal cord and motor function outcomes in Wistar rats post-induction of severe CMS in the acute phase. chronic.

 

This study is an experimental study using a post-test randomized controlled trial design. The subjects of this study were divided into three groups: normal control, negative control (induced by severe CMS), and treatment (induced by severe CMS and received MLC901). The data obtained were then analyzed using descriptive and inferential statistics, Receiver Operating Characteristics, and path analysis with a significance limit of 0.05.

 

Conclusion: Administration of MLC901 provides benefits for the motor and histopathological outcomes through the mechanism of suppressing the processes of gliosis, neuroapoptosis, and neuroinflammation in the Wistar rat model induced by severe CMS in the chronic phase.

 

The novelty of this study is to prove that there are improvements shown in NG2 expression, Caspase-3 expression, IL-10 levels, spinal cord histopathological degree, and motor function, thereby strengthening the CMS healing theory. Administration of MLC90 provides benefits for motor function and histopathological outcomes of the spinal cord through biomolecular mechanisms suppressing gliosis, neuroapoptosis, and neuroinflammation in an experimental animal model of Wistar rats induced by severe CMS in the chronic phase. This study also proved that administration of MLC901 showed an improvement in the histopathological picture of the spinal cord after severe CMS in the chronic phase based on a lower cavitation diameter.

 

 

The exam was led by the Dean of FK Unud Dr. dr. Komang Januartha Putra Pinatih, M.Kes. with the testing team:

1. Dr. dr. Sri Maliawan, Sp.BS (K)., FICS. (Promoter)

2. Prof. Dr. dr. Tjokorda Gde Bagus Mahadewa, M.Kes., Sp.BS (K) Spinal, FICS., FINSS. (Co-promoter I)

3. Dr. dr. I Made Jawi, M.Kes (Co-promoter II)

4. Dr. dr. I Made Bakta, Sp.PD-KHOM

5. Prof. Dr. dr. Andi Asadul Islam, Sp.BS(K)

6. Dr. Ir. Ida Bagus Putra Manuaba, M.Phill

7. drh. I Nyoman Mantik Astawa, Ph.D

8. Dr. dr. A.A.Wiradewi Lestari, Sp.PK(K)

9.Dr. dr. I Made Sudarmaja, M. Kes

 

While academic invitations are:

1.Dr. dr. Wira Gotera, Sp.PD-KEMD-FINASIM

2.Dr. dr. I Made Mulyawan, Sp.B.Subsp.BD(K)

3.Dr. dr. I Nyoman Wande, S.Ked.,Sp.PK(K)

4. dr. I Made Winarsa Ruma, S.Ked.,Ph.D

5.Dr. dr. I Wayan Eka Sutyawan, Sp. M(K)

 

In this exam, Dr. dr. Dewa Putu Wisnu Wardhana, Sp.BS., MD.FICS was declared to have passed as the 397th Graduate Doctor of the Doctoral Study Program in Medical Sciences, Faculty of Medicine, Udayana University with the title of Very Satisfying.